Analysts Offer Predictions for Organigram FY2027 Earnings

Organigram Holdings Inc. (TSE:OGI) – Stock analysts at Atb Cap Markets issued their FY2027 EPS estimates for shares of Organigram in a note issued to investors on Tuesday, February 11th. Atb Cap Markets analyst F. Gomes expects that the company will post earnings of $0.08 per share for the year. The consensus estimate for Organigram’s current full-year earnings is $0.16 per share. Atb Cap Markets also issued estimates for Organigram’s FY2028 earnings at $0.20 EPS.

Other equities research analysts also recently issued research reports about the stock. ATB Capital dropped their price target on shares of Organigram from C$5.25 to C$3.50 in a research note on Tuesday, December 17th. Canaccord Genuity Group cut their price target on Organigram from C$3.60 to C$3.15 and set a “speculative buy” rating on the stock in a research note on Monday, December 9th.

Organigram Stock Down 6.8 %

Shares of TSE:OGI opened at C$1.92 on Thursday. The company has a market capitalization of C$208.45 million, a price-to-earnings ratio of -0.76, a price-to-earnings-growth ratio of 0.42 and a beta of 1.13. The company has a 50 day moving average of C$2.24 and a two-hundred day moving average of C$2.32. The company has a quick ratio of 2.62, a current ratio of 6.95 and a debt-to-equity ratio of 1.13. Organigram has a 52-week low of C$1.86 and a 52-week high of C$3.95.

Organigram Company Profile

Organigram Inc is a Canadian licensed producer of cannabis products. Organigram focuses on producing exceptional, indoor-grown cannabis for patients and adult recreational consumers, as well as developing global business partnerships.